In a modern drug discovery setting, in vitro protein binding assays are essential to assess the binding affinity and characteristics of a drug molecule with plasma proteins. Two commonly used methods for in vitro protein binding assays are equilibrium dialysis and...
Modern Drug Discovery Workflows There are several reasons why it is important to introduce in vitro absorption, distribution, metabolism, and excretion (ADME) assays as early as possible into a modern drug discovery workflow, especially for biotech companies. Here are...
Brain tumors are a major cause of cancer-related death, and metastatic brain tumors are particularly difficult to treat. Brain tumors pose significant challenges to scientists in terms of understanding their development and progression, and finding effective treatment...
The race to first-in-human clinical trials has become more critical than ever for drug developers. The FDA has even developed 4 major tracks to speed up the process and make drugs available to patients as fast as possible: Fast Track: Facilitates drug development and...
A recently published article entitled Ex vivo engineered human plasma cellsexhibit robust protein secretion and long-term engraftment in vivo1 shows that a subset of in vitro cultured plasma B cells can take on characteristics of long-lived natural plasma B cells. Due...
This blog series presents links to new literature on topics of Medicinal and Organic Chemistry. It is derived from surveys of the Table of Contents for the Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, Journal of Organic Chemistry, Journal of the...
Employee Spotlight Our employee spotlight series celebrates the accomplishments and expertise of our valued scientists and staff. Dr. Lilly Xu Dr. Lilly Xu SVP and Head of DMPK and Exploratory Toxicology at ChemPartner Q&A with Dr. Xu How long have you been with...
PD-L1 is a key inhibitor of T cell activation that is often over-expressed in cancer to escape immune surveillance and promote tumor progression. Blocking antibodies against PD-L1 or its receptor, PD-1, have shown significant clinical benefit in some patients with...
Gileadʹs antiviral drug remdesivir (Veklury, 1) was approved by the FDA on May 1st for emergency use against coronavirus disease-2019 (COVID-19) after just a one-day review. Now the onerous task falls upon Gilead to make enough of the drug to supply doctors and...
On October 5, 2020, the Nobel Assembly at the Karolinska Institute announced the Nobel Prize for Physiology or Medicine went to Harvey J. Alter, Michael Houghton, and Charles M. Rice “for their discovery of hepatitis C virus (HCV).” The worldwide incidence of HCV...
